Menu
Search Close

Company

Management

Dr Cliff Holloway (CEO)

Cliff brings over 25 years of life science industry experience to Scancell in the development and commercialisation of emerging technologies and therapeutic products including licensing, M&A, corporate financing and operations management. Most recently he was Chief Business and Operating Officer of Benitec Biopharma Ltd (ASX:BLT, NASDAQ:BNTC). Prior to his role at  Benitec he held the position of Managing Director at Sienna Cancer Diagnostics Ltd (ASX:SDX), and also for therapeutic antibody development companies Immune System Therapeutics Ltd and Biosceptre International Ltd. He was formerly VP of Business Development at Arana Therapeutics Ltd, which was acquired by US-based Cephalon Inc (now Teva) in 2009, and he is currently a director of investment fund Newstar Ventures Pty Ltd. Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham.

Professor Lindy Durrant (CSO)

Lindy is an internationally recognised immunologist in the field of tumour therapy, She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham.

Dr Sally Adams (Development Director)

Dr Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specialising in biological entities.  She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction.  Sally previously  worked as a development consultant to  Scancell, providing guidance on the development  of SCIB1, before her appointment as Development Director in May 2014.

Keith Green (Director of Finance & Administration )

Keith trained and qualified as a chartered accountant with Peat Marwick (now KPMG). He spent twenty years in the accounting profession before joining a private medical diagnostic company as Financial Director. Since 2003 he has taken on many consultancy and interim finance roles for private and AIM listed companies in the life sciences sector. Keith started working for Scancell on a part-time basis in January 2010 and took up this full-time role in September 2016.

Scientific Papers

Novel tumour antigens and the development of optimal vaccine design (2018)

Victoria A Brentville, Suha Atabani, Katherine Cook and Lindy G Durrant


Current Strategies to Enhance Anti-Tumour Immunity (2018)

Katherine W Cook, Lindy G Durrant and Victoria A Brentville


Autophagy, citrullination and cancer (2016)

Lindy G. Durrant, Rachael L. Metheringham and Victoria A. Brentville


SCIB1 combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors (2016)

Wei Xue, Victoria A. Brentville, Peter Symonds, Katherine W. Cook, Hideo Yagita, Rachael L. Metheringham and Lindy G. Durrant


SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes (2016)

Wei Xue, Rachael L. Metheringham, Victoria A. Brentville, Barbara Gunn, Peter Symonds, Hideo Yagita, Judith M.  Ramage and Lindy G. Durrant


Citrullinated Vimentin presented on MHC-II in Tumor Cells is a target for CD4þ T-cell-mediated antitumor immunity (2016)

Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue and Lindy G. Durrant 


High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment (2012) 
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn and Lindy G. Durrant


Using monoclonal antibodies to stimulate antitumour cellular immunity (2011)
Lindy Durrant, Victoria Pudney and Ian Spendlove


Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses (2010)
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachael Metheringham


DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells (2009)
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant


Antibodies designed as effective cancer vaccines (2009)
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant



Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4 T-Cell–Mediated Antitumor Immunity

Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue, and Lindy G. Durrant


ASCO Poster June 2015

P.M Patel, C Ottensmeier, C Mulatero, P Lorigan, R Plummer, M Cunnell, R Metheringham, V Brentville, L Machado, I Daniels, D Hannaman, L.G Durrant


AACR Moditope® poster April 2015 

Victoria A Brentville, Rachael L Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Wei Xue, Lindy G Durrant


High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gun and Lindy G. Durrant


Using monoclonal antibodies to stimulate antitumour cellular immunity
Lindy Durrant, Victoria Pudney and Ian Spendlove

ASCO poster June 2014
P.M Patel, L.G Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, M. Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels and D. Hannaman


Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachel Metheringham


DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant


Antibodies designed as effective cancer vaccines
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant


Webcasts, Interviews and Media Coverage

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

Tue, 25 Sep 2018 06:20:00

Scancell Holdings extends collaboration with Sweden's Karolinska Institute

The company first teamed up with Sweden's world-leading medical research university two years ago

Thu, 09 Aug 2018 08:15:00

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems

Wed, 18 Jul 2018 06:09:00